Shopping Cart 0
Cart Subtotal
USD 0

TESARO Inc (TSRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The company's product portfolio includes ZEJULA (niraparib), to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and VARUBI (rolapitant) for the prevention of chemotherapy induced nausea and vomiting (CINV). TESARO sells its products directly to hospitals and clinics, and to a limited number of specialty distributors and pharmacy providers in the US and to certain wholesale distributors in Europe. TESARO is headquartered in Waltham, Massachusetts, the US.

TESARO Inc (TSRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10

TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

TESARO Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Tesaro Enters into Collaboration Agreement with Genentech 13

Tesaro and Medison Pharma Enter into Distribution Agreement 14

Tesaro Enters into Partnership with Genentech 15

OncoQuest Enters into Agreement with Tesaro 16

Evotec and Tesaro Enter into Agreement 17

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18

Licensing Agreements 19

TESARO Enters into Research and Licensing Agreement with TeneoBio 19

Millennium Pharma Enters into Licensing Agreement with Tesaro 20

Zai Lab Enters into Licensing Agreement with Tesaro 21

Janssen Biotech Enters into Licensing agreement with Tesaro 22

Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23

Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24

Tesaro Amends Licensing Agreement With AnaptysBio 25

Tesaro Enters into Licensing Agreement with AstraZeneca 26

Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27

Equity Offering 28

Tesaro Raises USD236.3 Million in Public Offering of Shares 28

Tesaro Raises USD433.2 Million in Public Offering of Shares 30

Tesaro Raises USD50 Million in Private Placement of Shares 32

Tesaro Raises up to USD155 Million in Private Placement of Shares 33

Tesaro Raises USD191.5 Million in Public Offering of Shares 35

Tesaro Completes Public Offering Of Shares For USD 100.8 Million 37

Tesaro Completes Public Offering Of Common Stock For USD 98 Million 38

Tesaro Announces Partial Exercise Of Underwriter's Option For IPO For USD 87 Million 39

Debt Offering 41

Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41

Asset Transactions 43

TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43

Acquisition 44

Tesaro May Sell Itself 44

TESARO Inc-Key Competitors 45

TESARO Inc-Key Employees 46

TESARO Inc-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Recent Developments 48

Financial Announcements 48

Nov 01, 2018: TESARO announces third-quarter 2018 operating results 48

Aug 02, 2018: TESARO announces second-quarter 2018 operating results 51

May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results 53

Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results 54

Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results 58

Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results 60

May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results 62

Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results 64

Government and Public Interest 66

May 08, 2018: Psychological Effects of Ovarian Cancer Often Overlooked But Can Have a Significant Impact on Patients 66

Product News 68

10/25/2017: TESARO Announces U.S. FDA Approval of VARUBI IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy 68

02/27/2017: TESARO Receives Positive CHMP Opinion for VARUBY 70

02/23/2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant) 71

01/12/2018: TESARO Announces Updates to the U.S. Prescribing Information for VARUBI (rolapitant) Injectable Emulsion 72

Product Approvals 73

Sep 11, 2017: NHS Scotland Recommends Tesaro's Varuby (Rolapitant) For Delayed Nausea And Vomiting In Adults Undergoing Highly Emetogenic Chemotherapy 73

Apr 26, 2017: TESARO Announces Approval of VARUBY (Oral Rolapitant Tablets) by European Commission 74

Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA 76

Clinical Trials 77

Nov 28, 2017: TESARO Announces Availability of VARUBI (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States 77

Sep 11, 2017: TESARO Summarizes TSR-042 Data Presented at 2017 ESMO Annual Meeting 79

Aug 25, 2017: TESARO Presents Poster on TSR-042 at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 80

Apr 27, 2017: TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 81

Other Significant Developments 82

Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing 82

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85


List Of Figure

List of Figures

TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

TESARO Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TESARO Inc, Deals By Therapy Area, 2012 to YTD 2018 9

TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10

TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Tesaro Enters into Collaboration Agreement with Genentech 13

Tesaro and Medison Pharma Enter into Distribution Agreement 14

Tesaro Enters into Partnership with Genentech 15

OncoQuest Enters into Agreement with Tesaro 16

Evotec and Tesaro Enter into Agreement 17

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18

TESARO Enters into Research and Licensing Agreement with TeneoBio 19

Millennium Pharma Enters into Licensing Agreement with Tesaro 20

Zai Lab Enters into Licensing Agreement with Tesaro 21

Janssen Biotech Enters into Licensing agreement with Tesaro 22

Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23

Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24

Tesaro Amends Licensing Agreement With AnaptysBio 25

Tesaro Enters into Licensing Agreement with AstraZeneca 26

Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27

Tesaro Raises USD236.3 Million in Public Offering of Shares 28

Tesaro Raises USD433.2 Million in Public Offering of Shares 30

Tesaro Raises USD50 Million in Private Placement of Shares 32

Tesaro Raises up to USD155 Million in Private Placement of Shares 33

Tesaro Raises USD191.5 Million in Public Offering of Shares 35

Tesaro Completes Public Offering Of Shares For USD 100.8 Million 37

Tesaro Completes Public Offering Of Common Stock For USD 98 Million 38

Tesaro Announces Partial Exercise Of Underwriter's Option For IPO For USD 87 Million 39

Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41

TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43

Tesaro May Sell Itself 44

TESARO Inc, Key Competitors 45

TESARO Inc, Key Employees 46

TESARO Inc, Subsidiaries 47

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

TESARO Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The company's product portfolio includes ZEJULA (niraparib), to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and VARUBI (rolapitant) for the prevention of chemotherapy induced nausea and vomiting (CINV). TESARO sells its products directly to hospitals and clinics, and to a limited number of specialty distributors and pharmacy providers in the US and to certain wholesale distributors in Europe. TESARO is headquartered in Waltham, Massachusetts, the US.

TESARO Inc (TSRO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10

TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

TESARO Inc, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Tesaro Enters into Collaboration Agreement with Genentech 13

Tesaro and Medison Pharma Enter into Distribution Agreement 14

Tesaro Enters into Partnership with Genentech 15

OncoQuest Enters into Agreement with Tesaro 16

Evotec and Tesaro Enter into Agreement 17

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18

Licensing Agreements 19

TESARO Enters into Research and Licensing Agreement with TeneoBio 19

Millennium Pharma Enters into Licensing Agreement with Tesaro 20

Zai Lab Enters into Licensing Agreement with Tesaro 21

Janssen Biotech Enters into Licensing agreement with Tesaro 22

Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23

Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24

Tesaro Amends Licensing Agreement With AnaptysBio 25

Tesaro Enters into Licensing Agreement with AstraZeneca 26

Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27

Equity Offering 28

Tesaro Raises USD236.3 Million in Public Offering of Shares 28

Tesaro Raises USD433.2 Million in Public Offering of Shares 30

Tesaro Raises USD50 Million in Private Placement of Shares 32

Tesaro Raises up to USD155 Million in Private Placement of Shares 33

Tesaro Raises USD191.5 Million in Public Offering of Shares 35

Tesaro Completes Public Offering Of Shares For USD 100.8 Million 37

Tesaro Completes Public Offering Of Common Stock For USD 98 Million 38

Tesaro Announces Partial Exercise Of Underwriter's Option For IPO For USD 87 Million 39

Debt Offering 41

Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41

Asset Transactions 43

TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43

Acquisition 44

Tesaro May Sell Itself 44

TESARO Inc-Key Competitors 45

TESARO Inc-Key Employees 46

TESARO Inc-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Recent Developments 48

Financial Announcements 48

Nov 01, 2018: TESARO announces third-quarter 2018 operating results 48

Aug 02, 2018: TESARO announces second-quarter 2018 operating results 51

May 03, 2018: TESARO Announces First-Quarter 2018 Operating Results 53

Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results 54

Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results 58

Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results 60

May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results 62

Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results 64

Government and Public Interest 66

May 08, 2018: Psychological Effects of Ovarian Cancer Often Overlooked But Can Have a Significant Impact on Patients 66

Product News 68

10/25/2017: TESARO Announces U.S. FDA Approval of VARUBI IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy 68

02/27/2017: TESARO Receives Positive CHMP Opinion for VARUBY 70

02/23/2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant) 71

01/12/2018: TESARO Announces Updates to the U.S. Prescribing Information for VARUBI (rolapitant) Injectable Emulsion 72

Product Approvals 73

Sep 11, 2017: NHS Scotland Recommends Tesaro's Varuby (Rolapitant) For Delayed Nausea And Vomiting In Adults Undergoing Highly Emetogenic Chemotherapy 73

Apr 26, 2017: TESARO Announces Approval of VARUBY (Oral Rolapitant Tablets) by European Commission 74

Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA 76

Clinical Trials 77

Nov 28, 2017: TESARO Announces Availability of VARUBI (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States 77

Sep 11, 2017: TESARO Summarizes TSR-042 Data Presented at 2017 ESMO Annual Meeting 79

Aug 25, 2017: TESARO Presents Poster on TSR-042 at the 2017 European Society for Medical Oncology (ESMO) Annual Meeting 80

Apr 27, 2017: TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042 81

Other Significant Developments 82

Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing 82

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85


List Of Figure

List of Figures

TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TESARO Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

TESARO Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

TESARO Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

TESARO Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

TESARO Inc, Deals By Therapy Area, 2012 to YTD 2018 9

TESARO Inc, Medical Devices Deals, 2012 to YTD 2018 10

TESARO Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Tesaro Enters into Collaboration Agreement with Genentech 13

Tesaro and Medison Pharma Enter into Distribution Agreement 14

Tesaro Enters into Partnership with Genentech 15

OncoQuest Enters into Agreement with Tesaro 16

Evotec and Tesaro Enter into Agreement 17

Myriad Genetics Enters into Research Agreement with Tesaro and Merck 18

TESARO Enters into Research and Licensing Agreement with TeneoBio 19

Millennium Pharma Enters into Licensing Agreement with Tesaro 20

Zai Lab Enters into Licensing Agreement with Tesaro 21

Janssen Biotech Enters into Licensing agreement with Tesaro 22

Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 23

Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 24

Tesaro Amends Licensing Agreement With AnaptysBio 25

Tesaro Enters into Licensing Agreement with AstraZeneca 26

Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 27

Tesaro Raises USD236.3 Million in Public Offering of Shares 28

Tesaro Raises USD433.2 Million in Public Offering of Shares 30

Tesaro Raises USD50 Million in Private Placement of Shares 32

Tesaro Raises up to USD155 Million in Private Placement of Shares 33

Tesaro Raises USD191.5 Million in Public Offering of Shares 35

Tesaro Completes Public Offering Of Shares For USD 100.8 Million 37

Tesaro Completes Public Offering Of Common Stock For USD 98 Million 38

Tesaro Announces Partial Exercise Of Underwriter's Option For IPO For USD 87 Million 39

Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 41

TerSera Therapeutics to Acquire North American Rights to Varubi from TESARO 43

Tesaro May Sell Itself 44

TESARO Inc, Key Competitors 45

TESARO Inc, Key Employees 46

TESARO Inc, Subsidiaries 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

TESARO Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.